Gilteritinib

• CAT Number: I001010
• CAS Number: 1254053-43-4
• Molecular Formula: C₂₉H₄₄N₈O₃
• Molecular Weight: 552.71
• Purity: 97%
• Synonyms: ASP2215
• Target: FLT3
• Target Protein: P36888
• Solubility: 10 mM in DMSO
• Appearance: Solid
• Storage: Dry, dark and at 2 - 8 °C for six months or -20°C for two years.
• IC50: IC50: 0.29 nM (FLT3) IC50: 0.73 nM (AXL)
• IUPAC Name: 6-ethyl-3-[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-(oxan-4-ylamino)pyrazine-2-carboxamide
• InChI: InChI=1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34)
• InChIKey: GYQYAJJFPNQOOW-UHFFFAOYSA-N
• SMILES: CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC(=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)OC)NC5CCOCC5

Gilteritinib（AT.:I001010）is a targeted therapy used to treat relapsed or refractory acute myeloid leukemia (AML) with FLT3 mutations. As a potent inhibitor of FLT3, Gilteritinib blocks both FLT3-ITD and FLT3-TKD mutations, which drive cancer cell proliferation and survival. By inhibiting these signaling pathways, Gilteritinib slows down the growth of leukemic cells, promoting cell death and reducing disease progression. Its targeted mechanism provides an effective treatment for patients with FLT3-mutated AML, improving outcomes in those resistant to standard therapies and offering a new option for managing this aggressive form of leukemia.